Diabetic peripheral neuropathy (DPN) affects roughly half of people who live with diabetes long enough, and loss of protective sensation is the single most important driver of foot ulceration. Because glucose control slows but rarely reverses nerve injury, there has been long-standing interest in agents that target the underlying mechanisms. Alpha-lipoic acid (ALA), an antioxidant that reduces oxidative stress in nerve tissue, is among the most studied. This article reviews what randomized trials and systematic reviews published since 2011 show about its effect on neuropathic symptoms, nerve impairment, and safety.
Why an Antioxidant for Nerve Damage?
Chronic hyperglycemia increases mitochondrial production of reactive oxygen species, depletes endogenous antioxidants, and reduces blood flow to peripheral nerves. ALA acts as a free-radical scavenger and regenerates other antioxidants, which led to a series of trials in the 1990s and 2000s. Most used the Total Symptom Score (TSS), which rates pain, burning, paresthesia, and numbness, and the Neuropathy Impairment Score (NIS), a clinician-examined measure of reflexes, strength, and sensation.
Early Trials and Meta-Analysis: Symptom Benefit With Caveats
Mijnhout and colleagues pooled four placebo-controlled trials (ALADIN, ORPIL, SYDNEY, and SYDNEY 2) in a 2012 meta-analysis in the International Journal of Endocrinology. The pooled standardized mean difference in TSS was −2.26 (95% CI −3.12 to −1.41), favoring ALA. The effect was larger with intravenous administration over about three weeks than with oral dosing, and the authors judged the oral effect probably not clinically relevant. Doses above 600 mg daily gave no added benefit and caused more nausea, vomiting, and dizziness. These trials were short, lasting three to five weeks, and they said little about long-term nerve function.
The NATHAN 1 Trial: Four Years of Follow-Up
NATHAN 1, published by Ziegler and colleagues in Diabetes Care in 2011, randomized 460 patients with mild-to-moderate sensorimotor polyneuropathy to 600 mg of ALA daily (n = 233) or placebo (n = 227) for four years. The primary composite endpoint, combining the NIS of the lower limbs with seven neurophysiologic tests, did not differ significantly between groups (P = 0.105). Secondary analyses favored ALA for change in NIS (P = 0.028) and NIS of the lower limbs (P = 0.05), and more ALA-treated patients showed clinically meaningful improvement and fewer showed progression. Nerve conduction and quantitative sensory tests did not differ significantly. Serious adverse events were more frequent with ALA (38.1%) than placebo (28.0%), although discontinuations due to intolerability were similar. The investigators noted that the placebo group did not deteriorate significantly on the primary endpoint, so the design could not fully test whether ALA prevents progression.
The Cochrane Review: A More Cautious Reading
The most rigorous synthesis is the 2024 Cochrane review by Baicus and colleagues, which included three randomized trials comparing 600 to 1800 mg of ALA daily with placebo in about 816 adults with type 1 or type 2 diabetes. At six months, ALA probably produced little or no change in the Total Symptom Score (mean difference −0.16 points; 95% CI −0.83 to 0.51; moderate-certainty evidence), a difference smaller than the minimal clinically important difference of 0.97 points. For the lower-limb impairment score, the estimate was −1.02 points (95% CI −2.93 to 0.89; low-certainty evidence), so a meaningful benefit could not be excluded. Adverse events leading to treatment cessation were probably no different from placebo (risk ratio 1.48; 95% CI 0.50 to 4.35). No included study reported quality of life, ulceration, or amputation, and all studies were at high risk of attrition bias.
A more recent meta-analysis by Das and colleagues in Exploration of Neuroprotective Therapy (2025) pooled nine randomized trials with 1,345 participants and reported improvements in TSS, NIS, vibration perception threshold, and global patient satisfaction, with no significant change in motor nerve conduction velocity or the lower-limb impairment score. Heterogeneity was high for several outcomes (I² up to 98%), which limits how confidently those pooled estimates can be applied to individual patients.
Interpreting the Evidence
The studies point in different directions because they measure different things over different time frames. Short trials using intravenous dosing show larger symptom effects; longer oral trials and the Cochrane analysis show small or uncertain effects. The consistent finding across reviews is that ALA is generally tolerated at 600 mg daily, while evidence for preventing ulceration or amputation is absent. Foot protection in neuropathy therefore continues to rest on risk stratification, regular examination, appropriate footwear, and glycemic control, with ALA best regarded as an agent with uncertain and modest symptomatic effects.
Key Takeaways
Alpha-lipoic acid is one of the most extensively studied antioxidant therapies for diabetic neuropathy, yet its benefit remains uncertain. Short-term and intravenous studies suggest symptom improvement, the four-year NATHAN 1 trial missed its primary endpoint while showing some secondary benefit, and the 2024 Cochrane review found probably little or no symptom effect at six months. No trial has demonstrated an effect on foot ulcers or amputation.
References
- Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. 2024;(1):CD012967.
- Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-2060.
- Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. International Journal of Endocrinology. 2012;2012:456279.
- Das S, Viswanatha GL, Nandakumar K, Kishore A, Hanumanthappa S. Alpha lipoic acid: advancing insights in diabetic neuropathy through updated systematic review and meta-analysis. Exploration of Neuroprotective Therapy. 2025;5(1):1004125.
Comments
